EXXUA's 138% sequential prescription growth and positive Adjusted EBITDA signal the launch is gaining traction. Monitor Q1 FY2027 for continued prescription acceleration and whether the company can sustain positive EBITDA as EXXUA scales.
Price Chart
Executive Summary
Aytu BioPharma reported fiscal Q4 2026 results with net revenue of $16.1M (+6.4% YoY), driven by $3.9M in EXXUA revenue in its first full launch quarter. The company posted a near-breakeven net loss of less than $0.1M and positive Adjusted EBITDA of $0.5M, compared to a net loss of $19.8M in Q4 2025. EXXUA prescriptions grew 138% sequentially to 3,323, signaling accelerating commercial adoption, though full-year revenue declined 13.3% to $57.6M due to legacy portfolio contraction.
Key Financial Metrics
Key Facts
- Q4 FY2026 net revenue $16.1M, +6.4% YoY from $15.1M
- EXXUA net revenue $3.9M in first full launch quarter, up from $2.4M in Q3
- EXXUA total prescriptions 3,323 in Q4, up ~138% from 1,398 in Q3
- Net loss near break-even at less than ($0.1)M vs ($19.8)M loss in Q4 2025
- Adjusted EBITDA positive at $0.5M vs $2.0M in Q4 2025
- Cash and cash equivalents $26.3M at June 30, 2026
- Full-year FY2026 net revenue $57.6M, -13.3% from $66.4M in FY2025
- Full-year Adjusted EBITDA ($3.7)M vs $9.2M in FY2025 due to EXXUA launch investments
- Derivative warrant liabilities reduced to $1.2M from $26.3M after March 2026 warrant amendment
Financial Impact
Q4 revenue beat consensus of $12.3M by 31%; EPS of ($0.00) beat consensus of ($0.35) by ~100%
Risk Factors
- EXXUA launch is still early; prescription growth may decelerate
- Legacy ADHD and Pediatric portfolios continue to decline due to generic competition and reduced promotion
- Full-year revenue declined 13.3%, and the company remains unprofitable on a GAAP basis
- Cash burn of $4.7M from June 2025 to June 2026; runway limited without revenue growth
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-030900 |
| Document: aytu20260502_8k.htm | 0001437749-26-030900 |
| Document: 0001437749-26-030900-index-headers.html | 0001437749-26-030900 |
| Document: 0001437749-26-030900-index.html | 0001437749-26-030900 |
| Document: 0001437749-26-030900.txt | 0001437749-26-030900 |
| 8-K Data (Synthetic) | 0001437749-26-030900 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | DEF 14A | $1.98 | awaiting T+20 | — | $1.93 (−2.53%) |
Sep 22, 2026 4w ago | 8-K | $2.28 $1.96 | ▼ −14.04% | ▼ −14.72% | $1.93 (−15.35%) |
Jun 25, 2026 17w ago | 8-K | $2.17 $2.16 | ▼ −0.46% | ▼ −1.72% | $1.93 (−11.06%) |
Apr 2, 2026 29w ago | 8-K | $2.66 $2.55 | ▲ +4.14% | ▲ +13.12% | $1.93 (+27.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers